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Abstract
There are no clear guidelines for the treatment of hepatic neuroendocrine tumours. Surgical resections — though rarely radical — seem to 
be the treatment of choice. Thermoablation, chemoembolisation, or cytoreductive surgery of hepatic focal lesions are often recommended. 
Pharmacological treatment is based on somatostatin analogues. Liver transplantation is available for a strictly selected group of patients 
with hepatic neuroendocrine tumours [5]. In the case described above, there were a number of factors that affected the decision about 
eligibility: first of all — very slow growth of the tumour, its size, and typical multifocality, which made it impossible to perform resection, 
lack of neoplastic focus outside the liver, and low Ki-67 proliferation index of ≤ 2%. The surgical risk was escalated due to the giant tumour 
mass and the laparotomy, which was performed twice. (endokrynol Pol 2019; 70 (6): 520–521)
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Introduction
Primary hepatic neuroendocrine tumours (PHNETs) 
are very rare. They constitute only 0.3% of all hepatic 
neuroendocrine tumours. The first report of a case 
of PHNET was provided by Edmondson in 1968 [1]. 
Until today, there have been approximately 150 cases 
described in the literature. PHNETs are tumours hard 
in their structure and clinically aggressive; they impair 
both the anatomy and function of the liver. The first 
symptoms are often the result of mass effect. PHNETs 
can be characterised with multifocality and very often 
lack of hormonal function activity. They are differ-
ent from other neuroendocrine tumours due to their 
asymptomatic and slow growth [2]. Primary hepatic 
neuroendocrine tumours may resemble hepatocellular 
carcinoma or metastatic lesions in CT imaging. His-
topathological assessment including positive synap-
tophysin (Syn) immunostaining and neuron-specific 
enolase are said to be a decisive diagnostic procedure. 
Long post-operative observation, with no primary sites 
identified in imaging, is crucial for the acknowledgment 
of a formal diagnosis [3].
There are no clear guidelines for treatment of PH-
NETs. Resection is deemed to be the first-line treatment. 
Systemic chemotherapy, radiotherapy, or transarterial 
chemoembolisation (TACE) fail to prolong the life of 
a patient [4]. Orthotopic liver transplantation is oc-
casionally applied.
Case study
In February 2008, in a 54-year-old female patient, 
who failed to report significant complaints, numer-
ous hepatic tumour-like and fluid-filled lesions were 
incidentally identified in ultrasound imaging, with the 
largest lesion having the diameter of 18 cm. Endoscopic 
and imaging examinations showed no primary site. 
The patient underwent laparotomy, which resulted 
in the conclusion that the lesions were non-resectable. 
The metastasis of adenocarcinoma mucocellulare was di-
agnosed in a histopathological test performed on the 
basis of the collected tissue samples. The patient was 
given six cycles of palliative chemotherapy (5-fluo-
rouracil and leucovorin), which was concluded in 
December 2008. No improvement was achieved, and 
due to intensified side effects, the patient refused to 
be treated any further.
The follow-up contrast-enhanced CT scan showed 
continued growth of tumour-like lesions in the liver. Af-
ter seven years, because the patient’s status was stable, 
a decision was made that relaparotomy was necessary 
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Conclusion
There are no clear guidelines for the treatment of hepatic 
neuroendocrine tumours. Surgical resections — though 
rarely radical — seem to be the treatment of choice. 
Thermoablation, chemoembolisation, or cytoreductive 
surgery of hepatic focal lesions are often recommended. 
Pharmacological treatment is based on somatostatin 
analogues. Liver transplantation is available for a strictly 
selected group of patients with hepatic neuroendocrine 
tumours [5]. In the case described above, there were 
a number of factors that affected the decision about eli-
gibility: first of all — very slow growth of the tumour, its 
size, and typical multifocality, which made it impossible 
to perform resection, lack of neoplastic focus outside 
the liver, and low Ki-67 proliferation index of ≤ 2%. The 
surgical risk was escalated due to the giant tumour mass 
and the laparotomy, which was performed twice.
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and that the histopathological diagnosis should be veri-
fied. The patient lost 30 kg of body mass. On the basis of 
immunochemistry [chromatogranin (+), Syn (+), TTF-1 
negative], well-differentiated endocrine tumour was 
diagnosed (Ki-67 index ≤ 2%). Somatostatin receptor 
(SSR) scintigraphy proved overexpression in the right 
hepatic tumour. 
In the face of this new diagnosis, stable general 
status, and the giant mass of the tumour, an initial deci-
sion that the patient was eligible for liver transplanta-
tion was taken. Upon deciding on her eligibility at the 
transplantation clinical hospital, the patient presented 
benign ascites. The degree of liver failure was assessed 
to be 9, in accordance with model of end-stage liver dis-
ease (MELD) and 6 in accordance with the Child-Pugh 
score. Levels were as follows: bilirubin — 0.66 mg%, 
creatinine — 1.17mg%, INR — 1.3, and albumin con-
centration — 4.40 g/L. The liver mass was estimated 
to be approx. 10 kg in CT scan (Fig. 1). Orthotopic 
liver transplantation was performed with a traditional 
technique and with use of a veno-venous pump in 
November 2016. The surgery took more than seven 
hours. The ‘leading tumour’, having a diameter of 35 
cm, was identified in the right lobe of the removed liver. 
The initial diagnosis was confirmed by histopathologi-
cal examination. No surgical complications occurred 
after the procedure. Immunosuppressive therapy 
was administered based on a three-drug regimen: 
tacrolimus, mycophenolate mofetil, and prednisone. 
Until now, the patient has not been diagnosed with 
a relapse. Follow-up PET/CT scan with 68Ga-DOTATATE 
revealed normal uptake without places of pathological 
expression of SSR (Fig. 2).
Figure 2. 68Ga-DOTATATE PET/CT scan. The examination 
revealed normal distribution without pathological somatostatin 
expression
Figure 1. CT scan with a dominant tumour of the right hepatic lobe
